
    
      The primary aim of the current study is:

        1. To evaluate the safety and efficacy of a supplemental probiotic therapy, containing the
           microorganisms Lactobacillus rhamnosus GG and Bifidobacterium lanimalis subsp. lactis
           (BB12), for individuals with schizophrenia who have residual psychotic symptoms of at
           least moderate severity.

           Secondary aims of the study are:

        2. To assess the effect of probiotic treatment on patients' gastrointestinal functioning

        3. To study the effect of probiotic treatment in lowering the levels of antibodies to
           casein and gliadin.

        4. To investigate the association between the efficacy of probiotic therapy and initial
           levels of antibodies to gliadin and casein.
    
  